噻吩并吡啶类药物代谢的研究进展

Research advance in metabolism of thienopyridines drugs

抗血小板治疗因其强有效的降低动脉血栓的能力,成为了缺血性心脑血管疾病患者治疗的基础。噻吩并吡啶类药物是第一批被开发的血小板ADP受体拮抗剂,其母体药物均为无活性的前药,需经体内代谢转化为活性产物后才能对ADP受体P2Y12发挥抑制作用。对噻吩并吡啶类药物的代谢途径、代谢产物及其临床相互作用进行了综述。

Anti-platelet therapy has become established as a cornerstone in the treatment of patients with ischaemic cardiovascular disease, since such drugs could effectively reduce arterial thrombotic events. Thienopyridine drugs are the first platelet adenosine diphosphate （ADP） receptor antagonists to be developed, which comprise inactive pro-drugs that require in vivo metabolism to their active metabolites before exerting their inhibitory effect on the P2Y12 receptor. The objective of this article is to summarize the metabolic pathways, metabolites, and clinical interactions among thienopyridine drugs.